Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Simply Wall StNov 16 22:25

Here's Why Inozyme Pharma (INZY) Is Poised for a Turnaround After Losing -29.98% in 4 Weeks

Zacks Nov 13 21:45

Inozyme Pharma to Present at Upcoming Investor Conferences

GlobeNewswireNov 11 21:30

Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16

Futu NewsNov 8 23:37 · Ratings

H.C. Wainwright Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $14

Futu NewsNov 6 19:33 · Ratings

TD Cowen Maintains Inozyme Pharma(INZY.US) With Buy Rating

Futu NewsNov 6 03:33 · Ratings